Last reviewed · How we verify
Treatment 90 days DAPT
At a glance
| Generic name | Treatment 90 days DAPT |
|---|---|
| Also known as | Subjects will be treated with Aspirin and P2Y12 inhibitor. Prasugrel (10, mg/day) or Ticagrelor (180 mg/day) are strongly recommended as compared, to Clopidogrel (75 mg/day))., Short term DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up, to 90 days, after which patients will continue. |
| Sponsor | Diagram B.V. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
- Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors (PHASE4)
- HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN) (PHASE3)
- PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy (NA)
- Rivaroxaban for Slow Coronary Flow After PCI in STEMI (PHASE4)
- SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy (PHASE2)
- A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment 90 days DAPT CI brief — competitive landscape report
- Treatment 90 days DAPT updates RSS · CI watch RSS
- Diagram B.V. portfolio CI